Pour L, Hájek R, Adam Z, Krejcí M, Vorlícek J
Interní hematoonkologická klinika Lékarské fakulty MU a FN Brno, pracoviste Bohunice.
Vnitr Lek. 2009 Sep;55(9):767-72.
Several randomized clinical trials in multiple myeloma (MM) completed in the last two decades have clearly shown that high-dose chemotherapy with hematopoietic stem cell support significantly increases the number of complete remissions and median overall survival in comparison to conventional chemotherapy. The median survival of MM patients treated with conventional chemotherapy is approximately 4 years in contrast to 5 to 6 years with autologous transplantation. Although high-dose chemotherapy with autologous transplantation is not curative and most patients will eventually relapse, more than 20% of patients treated using this strategy experience survival longer than 10 years. Thus, autologous transplantation is the preferred treatment option for all eligible patients with MM.
过去二十年中完成的多项针对多发性骨髓瘤（MM）的随机临床试验清楚地表明，与传统化疗相比，造血干细胞支持下的大剂量化疗显著增加了完全缓解的数量和中位总生存期。接受传统化疗的MM患者的中位生存期约为4年，而自体移植患者的中位生存期为5至6年。尽管自体移植的大剂量化疗不能治愈疾病，大多数患者最终会复发，但采用这种策略治疗的患者中超过20%的生存期超过10年。因此，自体移植是所有符合条件的MM患者的首选治疗方案。
